Home Depot Founder’s Foundation Makes Historic Medical Research Donation

The Marcus Foundation has committed $28.7 million to the University of Southern California (USC) to fund experimental stem cell research aimed at repairing heart muscle tissue damaged by myocardial infarctions. Directed by physician-scientist Charles “Chuck” Murry, the initiative seeks to advance gene-edited cellular therapies toward human clinical trials.

Here is the math: A severe heart attack blocks coronary arteries, starving cardiac tissue of oxygen and leaving behind non-contractile scar tissue that permanently degrades the organ’s pumping capacity. Traditional pharmacology manages symptoms but fails to regenerate lost muscle. The newly funded research at the USC Stem Cell Center, operating in partnership with the Keck Hospital of USC and a secondary site at the University of Washington, targets this exact structural deficit using lab-grown cardiomyocytes.

The Bottom Line

• The Capital Allocation: The $28.7 million commitment represents the largest single gift the Marcus Foundation has made to USC and a landmark investment in academic regenerative cardiology.
• The Clinical Timeline: Scheduled to commence in 2027, the initial phase will enroll approximately 18 patients suffering from extensive myocardial infarction to establish safety, feasibility, and cellular integration.
• The Technological Hurdle: Research programs concurrently address immune system responses and gene-editing modifications to eliminate the risk of dangerous arrhythmias and reduce reliance on immunosuppressive drugs.

Translating Biotechnology into Clinical Trials

The human heart possesses an extremely limited capacity for self-repair following a major ischemic injury. Dr. Chuck Murry’s team focuses on manufacturing specialized muscle cells known as cardiomyocytes from stem cells in a laboratory setting. According to reporting from The Times of India, these cells are designed to survive transplantation, integrate with native tissue, and actively contribute to cardiac contractions.

Photo: billionaires.africa

However, moving from preclinical animal models to human patients introduces significant bioengineering challenges. Unedited transplanted cells historically carry a high risk of causing abnormal heart rhythms if they fail to beat in exact synchronization with the host tissue. To mitigate this, Murry’s team utilizes advanced gene-editing techniques. As noted by Billionaires.Africa, Jonathan Simons, chief science officer of the Marcus Foundation, emphasized that this technological progression has finally advanced gene-edited cellular therapy to a stage where backing living medicine is viable.

The upcoming trial at Keck Hospital of USC marks a critical transition from basic academic research to regulated human evaluation. Carolyn Meltzer, dean of the Keck School of Medicine, and USC president Beong-Soo Kim have both highlighted the potential for this work to fundamentally alter the prognosis for millions of patients living with chronic heart failure resulting from scar tissue accumulation.

Philanthropic Legacy and Academic Medicine

The funding originates from the estate of the late Bernie Marcus, who co-founded Home Depot alongside Arthur Blank after both men were dismissed from Handy Dan. Marcus, who died in November 2024 with an estimated fortune of $11 billion, established the Marcus Foundation in 1989 with his wife, Billi, and became an early signatory to the Giving Pledge.

Photo: timesofindia.indiatimes.com

Medical philanthropy was a lifelong priority for Marcus, rooted in a childhood dream of becoming a doctor that went unfulfilled due to his family’s inability to afford medical school. Instead, he studied pharmacy at Rutgers University before building a retail empire. The foundation’s recent healthcare expenditures reflect a consistent strategy of backing high-risk, high-reward academic medicine. In 2024, the foundation allocated $25.9 million toward stroke research at the Emory University School of Medicine and Grady Health System’s Marcus Stroke and Neuroscience Center, alongside a $2 million grant to UCLA Health for stem cell research targeting spinal cord injuries.

Key Parameters of the USC Stem Cell Cardiac Initiative

Metric / Parameter	Details
Funding Allocation	$28.7 million from the Marcus Foundation
Lead Investigator	Dr. Chuck Murry, Director, USC Stem Cell Center
Target Clinical Trial Launch	2027 at Keck Hospital of USC
Initial Patient Cohort	Approximately 18 participants with extensive myocardial infarction
Secondary Research Site	University of Washington

Overcoming Immunological and Scaling Roadblocks

Beyond arrhythmia risks, the broader commercialization and practical scaling of cell-based cardiac therapies hinge on solving immunological rejection. A parallel research program funded under this initiative is specifically examining how the human immune system reacts to transplanted foreign cardiomyocytes. The ultimate objective is to minimize or entirely eliminate the necessity for long-term immunosuppressive drug regimens in patients receiving regenerative treatments.

While the preclinical data from animal studies demonstrate positive histological integration and reduced arrhythmic events, regulators demand rigorous human data. The 2027 trial is intentionally designed to monitor safety, cellular survival, and structural integration over long-term follow-up periods. Until these human trials generate peer-reviewed data, regenerative cardiac repair remains strictly experimental rather than an established clinical standard of care.

Disclaimer: The information provided in this article is for educational and informational purposes only and does not constitute financial advice.